Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

The two main players in the global obesity market are Eli Lilly LLY and Novo Nordisk NVO, with their respective GLP-1 ...

A groundbreaking initiative from the Trump administration could revolutionize access to costly weight-loss drugs under Medicare and Medicaid. This plan aims to provide millions of Americans suffering ...

Digestion issues, fatigue, and high costs haven’t stopped some from finding power and transformation through GLP-1 medications.

Danone is introducing an Oikos brand drink targeting U.S. consumers using weight loss medications such as Wegovy, pledging ...

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a ...

Eli Lilly is seeing strong growth from its weight loss drugs. Investors are nervous about tariffs on drugs and weak data from ...

Indianapolis-based Eli Lilly and Co. shares fell Thursday, Aug. 7 following the pharmaceutical company's second-quarter ...

I've been a science writer going on fifteen years now, but before that I worked as a certified personal trainer. In between ...

Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...